SN52

SN52 is a cell-permeable peptide inhibitor of the non-canonical (alternative) NF-κB pathway, designed to selectively block the nuclear translocation of the RelB:p52 heterodimer. Developed by researchers at the University of Kentucky, SN52 is a variant of the SN50 peptide, where the p50 nuclear localization signal (NLS) is replaced with the p52 NLS. By competing with p52 for nuclear import proteins (such as importin-α1 and importin-β1), SN52 prevents the nuclear import of RelB:p52 without affecting the canonical NF-κB pathway (RelA:p50). Preclinically, SN52 has been shown to enhance the radiosensitivity of aggressive prostate cancer cells by suppressing radiation-induced manganese superoxide dismutase (MnSOD/SOD2) expression, and to reverse tamoxifen resistance in breast cancer by regulating GPx4 and promoting ferroptosis. It is primarily utilized as a research reagent.

Other names

NF-kB Inhibitor SN52NF-kappaB Inhibitor SN52SN52 peptideSN-52 peptideSN 52 peptide